Estats Units - anglès - NLM (National Library of Medicine)

e-z-em canada inc - barium sulfate (unii: 25bb7eke2e) (barium sulfate - unii:25bb7eke2e) - barium sulfate .81 g in 1 g - varibar thin liquid is indicated for modified barium swallow examinations to evaluate the oral and pharyngeal function and morphology in adult and pediatric patients. varibar thin liquid is contraindicated in patients with: - known or suspected perforation of the gastrointestinal (gi) tract - known obstruction of the gi tract - high risk of gi perforation such as those with a recent gi perforation, acute gi hemorrhage or ischemia, toxic megacolon, severe ileus, post gi surgery or biopsy, acute gi injury or burn, or recent radiotherapy to the pelvis - high risk of aspiration such as those with known or suspected tracheo-esophageal fistula or obtundation - known severe hypersensitivity to barium sulfate or any of the excipients of varibar thin liquid risk summary varibar thin liquid is not absorbed systemically following oral administration, and maternal use is not expected to result in fetal exposure to the drug. risk summary varibar thin liquid is not absorbed systemically by the mother following oral adminis

Estats Units - anglès - NLM (National Library of Medicine)

e-z-em canada inc - barium sulfate (unii: 25bb7eke2e) (barium sulfate - unii:25bb7eke2e) - barium sulfate 20 mg in 1 ml - readi-cat 2 and readi-cat 2 smoothies are indicated for use in computed tomography (ct) of the abdomen to delineate the gastrointestinal (gi) tract in adult and pediatric patients. readi-cat 2 products are contraindicated in patients: - with known or suspected perforation of the gi tract - with known obstruction of the gi tract - at high risk of gi perforation such as those with a recent prior gi perforation, acute gi hemorrhage or ischemia, toxic megacolon, severe ileus, post gi surgery or biopsy, acute gi injury or burn, or recent radiotherapy to pelvis - at high risk of aspiration such as those with prior aspiration, tracheo-esophageal fistula, or obtundation - known severe hypersensitivity to barium sulfate or any of the excipients of readi-cat 2 or readi-cat 2 smoothies risk summary readi-cat 2 products are not absorbed systemically following oral administration, and maternal use is not expected to result in fetal exposure to the drug. risk summary readi-cat 2 products are not absorbed systemically by

Estats Units - anglès - NLM (National Library of Medicine)

e-z-em canada inc - barium sulfate (unii: 25bb7eke2e) (barium sulfate - unii:25bb7eke2e) - barium sulfate 400 mg in 1 ml - varibar pudding is indicated for modified barium swallow examinations to evaluate the oral and pharyngeal function and morphology in adult and pediatric patients 6 months of age and older. varibar pudding is contraindicated in patients with: - known or suspected perforation of the gastrointestinal (gi) tract; - known obstruction of the gi tract; - high risk of gi perforation such as those with a recent gi perforation, acute gi hemorrhage or ischemia, toxic megacolon, severe ileus, post gi surgery or biopsy, acute gi injury or burn, or recent radiotherapy to the pelvis; - high risk for aspiration such as those with known or suspected tracheo-esophageal fistula or obtundation; - known hypersensitivity to barium sulfate or any of the excipients of varibar pudding. risk summary varibar pudding is not absorbed systemically following oral administration, and maternal use is not expected to result in fetal exposure to the drug. [see clinical pharmacology (12.3)] risk summary varibar pudding is not absorbed syste

Estats Units - anglès - NLM (National Library of Medicine)

e-z-em canada inc - barium sulfate (unii: 25bb7eke2e) (barium sulfate - unii:25bb7eke2e) - barium sulfate 400 mg in 1 ml - varibar nectar is indicated for use in modified barium swallow examinations to evaluate the oral and pharyngeal function and morphology in adult and pediatric patients. varibar nectar is contraindicated in patients with: - known or suspected perforation of the gi tract - known obstruction of the gi tract - high risk of gi perforation such as those with a recent prior gi perforation, acute gi hemorrhage or ischemia, toxic megacolon, severe ileus, post gi surgery or biopsy, acute gi injury or burn, or recent radiotherapy to the pelvis - high risk for aspiration such as those with known or suspected tracheo-esophageal fistula or obtundation - known severe hypersensitivity to barium sulfate or any of the excipients of varibar nectar risk summary varibar nectar is not absorbed systemically following oral administration, and maternal use is not expected to result in fetal exposure to the drug [see clinical pharmacology (12.3)] . risk summary varibar nectar is not absorbed systemically by the mother following oral a

Estats Units - anglès - NLM (National Library of Medicine)

e-z-em canada inc - barium sulfate (unii: 25bb7eke2e) (barium sulfate - unii:25bb7eke2e) - barium sulfate 980 mg in 1 g - e-z-hd is indicated for use in double-contrast radiographic examinations of the esophagus, stomach and duodenum to help visualize the gastrointestinal (gi) tract in patients 12 years and older. e-z-hd is contraindicated in patients: - known or suspected perforation of the gi tract - known obstruction of the gi tract - at high risk of gi perforation such as those with a recent prior gi perforation, acute gi hemorrhage or ischemia, toxic megacolon, severe ileus, post gi surgery or biopsy, acute gi injury or burn, or recent radiotherapy to the pelvis - at high risk of aspiration such as those with prior aspiration, tracheo-esophageal fistula, or obtundation - with known severe hypersensitivity to barium sulfate or any of the e-z-hd excipients risk summary e-z-hd is not absorbed systemically following oral administration, and maternal use is not expected to result in fetal exposure to the drug. risk summary e-z-hd is not absorbed systemically by the mother following oral administration, and breastfeeding is not

Estats Units - anglès - NLM (National Library of Medicine)

e-z-em canada inc - barium sulfate (unii: 25bb7eke2e) (barium sulfate - unii:25bb7eke2e) - barium sulfate 0.6 g in 1 ml - liquid e-z-paque is indicated for use in single contrast radiographic examinations of the esophagus, stomach, and small bowel to visualize the gastrointestinal (gi) tract in adult and pediatric patients. liquid e-z-paque is contraindicated in patients with the following conditions: - known or suspected perforation of the gi tract - known obstruction of the gi tract - high risk of gi perforation such as those with a recent gi perforation, acute gi hemorrhage or ischemia, toxic megacolon, severe ileus, post gi surgery or biopsy, acute gi injury or burn, or recent radiotherapy to the pelvis - high risk of aspiration such as those with prior aspiration, tracheo-esophageal fistula, or obtundation - known severe hypersensitivity to barium sulfate or any of the excipients of liquid e-z-paque risk summary liquid e-z-paque is not absorbed systemically following oral administration, and maternal use is not expected to result in fetal exposure to the drug [see clinical pharmacology (12.3)] . risk summary liquid e-z-pa

Estats Units - anglès - NLM (National Library of Medicine)

e-z-em canada inc - barium sulfate (unii: 25bb7eke2e) (barium sulfate - unii:25bb7eke2e) - barium sulfate 960 mg in 1 g - e-z-paque is indicated for use in single contrast radiographic examinations of the esophagus, stomach, duodenum and small bowel to visualize the gastrointestinal tract (gi) in adult and pediatric patients. e-z-paque is contraindicated in patients with the following conditions: - known or suspected perforation of the gi tract - known obstruction of the gi tract - high risk of gi perforation such as those with a recent prior gi perforation, acute gi hemorrhage or ischemia, toxic megacolon, severe ileus, post gi surgery or biopsy, acute gi injury or burn, or recent radiotherapy to the pelvis - high risk of aspiration such as those with prior aspiration, tracheo-esophageal fistula, or obtundation - with known severe hypersensitivity to barium sulfate or any of the excipients of e-z-paque risk summary e-z-paque is not absorbed systemically following oral administration, and maternal use is not expected to result in fetal exposure to the drug [see clinical pharmacology (12.3)] . risk summary e-z-paque is not absorb

Estats Units - anglès - NLM (National Library of Medicine)

e-z-em canada inc - barium sulfate (unii: 25bb7eke2e) (barium sulfate - unii:25bb7eke2e) - barium sulfate 240 mg in 1 ml - entero vu 24% is indicated for use in small bowel radiographic examinations to visualize the gastrointestinal (gi) tract in adult patients. entero vu 24% is contraindicated in patients with the following conditions: - known or suspected perforation of the gi tract - known obstruction of the gi tract - high risk of gi perforation such as those with a recent gi perforation, acute gi hemorrhage or ischemia, toxic megacolon, severe ileus, post gi surgery or biopsy, acute gi injury or burn, or recent radiotherapy to the pelvis - high risk of aspiration such as those with known or suspected tracheo-esophageal fistula or obtundation - known severe hypersensitivity to barium sulfate or any of the excipients of entero vu 24% risk summary entero vu 24% is not absorbed systemically following oral administration, and maternal use is not expected to result in fetal exposure to the drug. risk summary entero vu 24% is not absorbed systemically by the mother following oral administration, and breastfeeding is not expected to

Canadà - anglès - Health Canada

total health centre - barium chloride - liquid - 6x - barium chloride 6x - homeopathic products

Nova Zelanda - anglès - Ministry for Primary Industries

agresearch ltd - selenium present as barium selenate - selenium present as barium selenate 24 g/litre - parenteral nutrient/electrolyte